Protalix BioTherapeutics competitorsClear all

Protalix BioTherapeutics's top competitors include Pharming Group, Biogen, MyoKardia and Athersys.
Protalix BioTherapeutics
Protalix BioTherapeutics
Protalix is a biopharmaceutical company focused on the development, production, and commercialization of recombinant therapeutic proteins.
Pharming Group
Pharming Group
Pharming Group is a biopharmaceutical company developing protein replacement therapies and precision medicines for the treatment of rare diseases.
Biogen
Biogen
Biogen is a biopharmaceutical company that discovers, develops, and delivers innovative therapies for people living with serious neurological and neurodegenerative diseases.
MyoKardia
MyoKardia
MyoKardia discovers, develops and commercializes targeted therapies for the treatment of serious and neglected rare cardiovascular diseases.
Athersys
Athersys
Athersys, a biopharmaceutical company, discovers and develops therapeutic products for the treatment of several disease indications.
Founding Date
Founding Date
1994
Founding Date
1988
Founding Date
1978
Founding Date
2012
Founding Date
1995
Type
Type
Public
Type
Public
Type
Public
Type
Public
Type
Public
Tags
Locations
Locations
Karmiel, IL HQ
Locations
Leiden, NL HQ
Leiden, NL
Locations
Cambridge, US HQ
Vicente López, AR
Macquarie Park, AU
Wien, AT
Machelen, BE
São Paulo, BR
Mississauga, CA
see more
Locations
South San Francisco, US HQ
Brisbane, US
Locations
Cleveland, US HQ
Canton, US
Employees
Employees
1843% decrease
Employees
258
Employees
7,4005% decrease
Employees
23542% increase
Employees
8311% increase
Valuation ($)
Valuation ($)
N/A
Valuation ($)
930.1 m
Valuation ($)
40.8 b
Valuation ($)
12 b
Valuation ($)
395.4 m
Twitter followers
Twitter followers
N/A
Twitter followers
N/A
Twitter followers
36.4 k
Twitter followers
1.2 k
Twitter followers
2 k
Number of tweets (last 30 days)
Number of tweets (last 30 days)
N/A
Number of tweets (last 30 days)
N/A
Number of tweets (last 30 days)
19
Number of tweets (last 30 days)
N/A
Number of tweets (last 30 days)
4
Average likes per tweet (last 30 days)
Average likes per tweet (last 30 days)
N/A
Average likes per tweet (last 30 days)
N/A
Average likes per tweet (last 30 days)
21.5
Average likes per tweet (last 30 days)
N/A
Average likes per tweet (last 30 days)
21.3
Percentage of tweets with engagement (last 30 days)
Percentage of tweets with engagement (last 30 days)
N/A
Percentage of tweets with engagement (last 30 days)
N/A
Percentage of tweets with engagement (last 30 days)
94.74%
Percentage of tweets with engagement (last 30 days)
N/A
Percentage of tweets with engagement (last 30 days)
100%
Alexa Website Rank
Alexa Website Rank
361368
Alexa Website Rank
297164
Alexa Website Rank
254464
Alexa Website Rank
239431
Alexa Website Rank
175823
Employee Rating
Employee Rating
5
Employee Rating
5
Employee Rating
4.1
Employee Rating
4.2
Employee Rating
4

Financial

Revenue (est.)
Revenue (est.)
$54.7m (FY, 2019)
Revenue (est.)
€169m (FY, 2019)
Revenue (est.)
$14.4b (FY, 2019)
Revenue (est.)
N/A
Revenue (est.)
$5.6m (FY, 2019)
Cost of goods
Cost of goods
$10.9m (FY, 2019)
Cost of goods
€21.4m (FY, 2019)
Cost of goods
$2b (FY, 2019)
Cost of goods
N/A
Cost of goods
N/A
Gross profit
Gross profit
$43.8m (FY, 2019)
Gross profit
€147.7m (FY, 2019)
Gross profit
$12.4b (FY, 2019)
Gross profit
N/A
Gross profit
N/A
Net income
Net income
($18.3m) (FY, 2019)
Net income
€36.2m (FY, 2019)
Net income
$5.9b (FY, 2019)
Net income
($276.2m) (FY, 2019)
Net income
($44.6m) (FY, 2019)

Operating

Patents (US)
Patents (US)
N/A
Patents (US)
N/A
Patents (US)
21 (FY, 2019)
Patents (US)
2 (FY, 2018)
Patents (US)
21 (FY, 2016)
Patents Issued
Patents Issued
N/A
Patents Issued
N/A
Patents Issued
34 (FY, 2019)
Patents Issued
N/A
Patents Issued
200 (FY, 2016)
Phase I Trials Products
Phase I Trials Products
N/A
Phase I Trials Products
2 (Q3, 2020)
Phase I Trials Products
13 (Q3, 2020)
Phase I Trials Products
1 (FY, 2018)
Phase I Trials Products
N/A
Phase II Trials Products
Phase II Trials Products
N/A
Phase II Trials Products
1 (Q3, 2020)
Phase II Trials Products
9 (Q3, 2020)
Phase II Trials Products
2 (FY, 2018)
Phase II Trials Products
N/A
Phase III Trials Products
Phase III Trials Products
N/A
Phase III Trials Products
N/A
Phase III Trials Products
6 (Q3, 2020)
Phase III Trials Products
1 (FY, 2018)
Phase III Trials Products
N/A

Funding

Total funding raised
Total funding raised
$ 62.5m
Total funding raised
N/A
Total funding raised
N/A
Total funding raised
$ 98m
Total funding raised
$ 9m
For sources of this data, please see the company profile

View company profiles

Pharming Group
HQ
Leiden, NL
Employees
258

Pharming Group is a biopharmaceutical company developing protein replacement therapies and precision medicines for the treatment of rare diseases.

View company
Biogen
HQ
Cambridge, US
Employees
7,400↓ 5% decrease

Biogen is a biopharmaceutical company that discovers, develops, and delivers innovative therapies for people living with serious neurological and neurodegenerative diseases.

View company
MyoKardia
HQ
South San Francisco, US
Employees
235↑ 42% increase

MyoKardia discovers, develops and commercializes targeted therapies for the treatment of serious and neglected rare cardiovascular diseases.

View company
Athersys
HQ
Cleveland, US
Employees
83↑ 11% increase

Athersys, a biopharmaceutical company, discovers and develops therapeutic products for the treatment of several disease indications.

View company